PREFORMULATION SCREENING OF REPAGLINIDE FOR TRANSDERMAL ANTI-DIABETIC THERAPY
The aim of the present work is to study the preformulation parameters for Transdermal drug delivery system. The objective of Preformulation study is to generic information useful to the formulater in developing stable and bioavailable dosage form. The use of Preformulation parameter maximizes the chances in formulation an acceptable, safe, efficacious and stable product and at the same time provide the basis for optimization of the drug product quality. Administration of conventional tablets of repaglinide has been reported to exhibit fluctuations in plasma drug levels, resulting either in manifestation of side effects or reduction in drug concentration at the receptor sites also, the maintenance of a constant plasma concentration of a anti-diabetic drug is important in ensuring the desired therapeutic response, again since the half life of repaglinide isÂ 01 hour hence multiple doses of the drug are needed to maintain a constant plasma concentration for a good therapeutic response, and improve patient compliance, hence the objective of the study was made to develop controlled release Transdermal Drug Delivery System of repaglinide using polymer like Eudragit RS 100, Eudragit RL 100 and HPMC, which will controlled the release of drug, increasing the bioavailability of the drug and thus decreasing the dosing frequency of the drug. The Preformulation studies were carried out in terms of test for identification (physical appearance, melting point, and uv spectrophotometer), solubility profile, determination of partition coefficient and quantitative estimation of drug. All the observation and results showed that the repaglinide could serve as suitable candidate for Transdermal drug delivery system that may improve the bioavailability.
Keywords: Transdermal, Repaglinide, Preformulation, Half Life, bioavailability
2. Chien YW. Transdermal therapeutic systems. In: Robinson JR, Lee V. H. editors. Controlled drug delivery: Fundamentals and applications. New York: Marcel Dekker; 1987, p. 524-549.
3. Tripathi KD. Insulin, oral hypoglycemics and glucagons, in: Essentials of Medical Pharmacology. 6th edition, Jaypee Brothers Medical Publishers (P) Ltd., New Delhi, 2008: 235.
4. Dornhorst Anne. Insulinotropic meglitinide analogues; New drug classes. The Lancet 2001; 358:1709-16
5. Ambavane V, Patil R and Aina SS. Repaglinide: A short acting insulin secretogogue for post prandial hyperglycaemia. J Postgrad Med 2002; 48:246-48.
6. Repaglinide,The free enclycopedia : "http://en.wikipedia.org/wiki/Repaglinide"
7. Flood TM. Appropriate use of insulin analogs in an increasingly complex type 2 Diabetes Mellitus (T2DM) therapeutic landscape. Supplement to the Journal of Family Practice, January 2007: S1-S12.
8. Grant P and Dashora U. The incretin effect and the use of Dipeptidy peptidase- 4 inhibitors. Int J Diab Dev Ctries September 2007; 27(3): 65-8.
9. Blickle JF. Meglitinide analogues: a review of clinical data focused on recent trials. Diabetes Metab 2006; 32:113-20.
10. Brunton LL, Lazo JS and Parker KL. Eds. Goodman & Gilmanâ€™s â€“ The Pharmacological Basis of Therapeutics. 11th edition. Mc Graw-Hill, medical publishing division; 2006: 1637-8, 1867.
11. Sweetman SC. editor. Martindale, The Complete Drug Reference. 35th edition: 415.
12. Gandhimathi M, Ravi TK, and Renu SK. Determination of Repaglinide in Pharmaceutical Formulations by HPLC with UV Detection. Analytical Sciences 2003; 19: 1675-77.
13. Pharmaceutics- The science of Dosage Form Design by M. E. Aulton. (2nd edition): pg.113
14. The Science & Practice of Pharmacy by Remington.(19th edition): pg.1447
15. The Theory & Practice of Industrial Pharmacy by Leon Lachman, Herbet A. Lieberman, Joseph L. Kaing.(3rd edition): pg.171
16. Modern Pharmaceutics by G. S. Banker & C. T. Rhodes. (4th edition): pg.211
17. Pharmaceutical Dosage Forms by Leon Lachman, H. A. Lieberman; Vol.1: pg.1
18. Pharmaceutical Dosage Forms & Delivery Systems by H.C. Ansel, L.V.Allen, N.G.Popvich; (7th edition): pg.64
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).